A general principle is that differential diagnoses should be diligently evaluated according to standard medical practice. Non- inflammatory etiologies should be considered and a ppropriately treated. Corticosteroids are a primary th erapy for immuno-oncology drug-related adverse events. The oral equivalent of the recommended IV doses may be considered for ambulatory patients with low- grade toxicity. The lower bioavailability of oral corticosteroids should be taken into account when switching to the equivalent dose of oral corticosteroids. Consultation with a medical or surgical specialist, especially prior to an invasive diagnostic or therapeutic procedure, is recommended.